Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2025)

Harmony Biosciences Holdings' FCF Margin history spans 6 years, with the latest figure at 51.7% for Q4 2025.

  • For Q4 2025, FCF Margin rose 1442.0% year-over-year to 51.7%; the TTM value through Dec 2025 reached 40.06%, up 946.0%, while the annual FY2025 figure was 40.06%, 946.0% up from the prior year.
  • FCF Margin for Q4 2025 was 51.7% at Harmony Biosciences Holdings, up from 45.38% in the prior quarter.
  • Across five years, FCF Margin topped out at 51.7% in Q4 2025 and bottomed at 18.33% in Q1 2025.
  • The 5-year median for FCF Margin is 36.51% (2023), against an average of 33.99%.
  • The largest annual shift saw FCF Margin skyrocketed 15558bps in 2021 before it plummeted -2036bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 41.15% in 2021, then crashed by -49bps to 20.79% in 2022, then surged by 119bps to 45.46% in 2023, then fell by -18bps to 37.29% in 2024, then soared by 39bps to 51.7% in 2025.
  • Per Business Quant, the three most recent readings for HRMY's FCF Margin are 51.7% (Q4 2025), 45.38% (Q3 2025), and 39.56% (Q2 2025).